HLS Therapeutics Inc.
HLS.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.99M | -19.66M | -22.03M | -24.09M | -27.85M |
| Total Depreciation and Amortization | 22.16M | 22.72M | 24.33M | 27.03M | 29.54M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.81M | 3.80M | 4.00M | 4.84M | 6.50M |
| Change in Net Operating Assets | 2.79M | 1.14M | 2.23M | 4.62M | 4.36M |
| Cash from Operations | 10.77M | 8.00M | 8.53M | 12.40M | 12.55M |
| Capital Expenditure | -34.00K | -15.00K | -16.00K | -16.00K | -43.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1.50M | -1.50M | -1.50M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 13.25M | 13.25M | 13.25M | 13.21M | -148.00K |
| Cash from Investing | 11.72M | 11.74M | 11.73M | 13.19M | -191.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -22.46M | -21.57M | -22.23M | -9.46M | -9.40M |
| Issuance of Common Stock | -- | -- | 0.00 | 0.00 | 0.00 |
| Repurchase of Common Stock | -493.00K | -600.00K | -1.18M | -1.78M | -1.65M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | 0.00 | 0.00 | -1.22M |
| Other Financing Activities | -658.00K | -1.19M | -1.19M | -2.55M | -1.89M |
| Cash from Financing | -23.61M | -23.36M | -24.60M | -13.79M | -14.16M |
| Foreign Exchange rate Adjustments | -584.00K | -870.00K | 62.00K | -218.00K | 32.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.71M | -4.50M | -4.27M | 11.58M | -1.77M |